Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Nomura Holdings Inc.

Nomura Holdings Inc. lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 71.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,888 shares of the company's stock after selling 37,118 shares during the quarter. Nomura Holdings Inc.'s holdings in Moderna were worth $619,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of MRNA. Wilmington Savings Fund Society FSB boosted its position in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. Compass Planning Associates Inc purchased a new position in Moderna in the 4th quarter valued at $37,000. Crowley Wealth Management Inc. purchased a new position in Moderna in the 4th quarter valued at $41,000. Finally, Itau Unibanco Holding S.A. increased its stake in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Price Performance

NASDAQ MRNA traded down $0.46 during trading on Friday, reaching $26.26. 8,237,982 shares of the company's stock were exchanged, compared to its average volume of 7,997,199. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The business has a 50 day moving average price of $27.23 and a 200-day moving average price of $34.81. The stock has a market capitalization of $10.16 billion, a P/E ratio of -2.83 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. During the same period in the prior year, the company earned ($3.07) earnings per share. The company's quarterly revenue was down 35.3% on a year-over-year basis. On average, analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of recent analyst reports. Bank of America cut their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Evercore ISI decreased their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Barclays decreased their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Royal Bank of Canada decreased their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Finally, Morgan Stanley decreased their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.